ATXN2 and amyotrophic lateral sclerosis: A few other treatments will utilize multimodal and precision therapies, given the genetic and biomarker profiles of the patients, to usher in a new treatment pipeline for ALS, especially for genetic variants impacting SOD1, C9orf72, TARDBP, ATXN2, and FUS [221].